ENGLEWOOD, Colo., March 1, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) will host an investor conference call Tuesday, March 7th at 4:30 pm EST. Participants are invited to dial-in using the instructions as listed below.
Investor call information:
U.S./Canada toll-free number: 888-401-4685
International toll number: 719-325-2144
Participant Passcode: 6053111
Presentation and dial in instructions will be posted on the Ampio website under the investor tab. www.ampiopharma.com
If you have any questions regarding the dial-in information, please call April Ramirez (720) 437-6524.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
Ampio's statements in this press release that are not historical fact, and that relate to future- plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "proposed," "will," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to the Ampion™, and the best path forward to obtain a Biological License, as well as risks associated with clinical trials, expected results, regulatory approvals, our ability to complete future investor conference calls to discuss the Company's strategies moving forward and changes in business conditions and similar events. These forward-looking statements also include statements regarding our perception of the guidance given to us from CBER related to our proposed small pre-approval study and how the Ampion™ label might be defined and what we will seek for the label to state. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Gregory A. Gould
Chief Financial Officer
Phone: (720) 437-6500
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ampio-hosting-conference-call-tuesday-march-7-430pm-est-300415667.html
SOURCE Ampio Pharmaceuticals, Inc.